Roche's Itovebi was the first PI3K inhibitor to get approved as a first-line treatment for breast cancer last year – and new ...

In particular, the organisation is unhappy with Kennedy's repeated assertions that Alzheimer's research has been dedicated to ...

While not the first biologic to break into the COPD sector – Sanofi and Regeneron took that crown with the approval of their ...

Final draft guidance from NICE has backed NHS use of Filspari (sparsentan) for primary immunoglobulin A nephropathy (IgAN), ...

Shares in the digital therapeutics (DTx) developer closed up more than 17% after its debut on the NYSE at $32 under the HNGE ...

To remain relevant in an interconnected ecosystem, biopharma must go beyond optimising yesterday’s markets and begin ...

AstraZeneca has turned to another digital health partner to support its aspirations in chronic kidney disease (CKD), joining ...

NICE is also looking at the role of Hympavzi in treating severe haemophilia A, where there are other subcutaneous options ...

Arguably, the step historically limiting growth of the radiotherapeutics sector is radioisotope generation. Isotopes are ...

According to the CDC, cases of myocarditis and pericarditis are rare with the vaccines and, in most cases, resolve within a ...

The $8-per-share deal will give Sanofi control of Vigil's VG-3927, an oral drug candidate for Alzheimer's that acts as an ...

For J&J, there was a positive outcome as the Oncologic Drugs Advisory Committee (ODAC) voted six to two in favour of approval ...